Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Aug;75(12):1349-71.
doi: 10.1007/s40265-015-0435-5.

A Review of Nebivolol Pharmacology and Clinical Evidence

Affiliations
Free PMC article
Review

A Review of Nebivolol Pharmacology and Clinical Evidence

Justin Fongemie et al. Drugs. .
Free PMC article

Abstract

Nebivolol is a highly selective β1-adrenergic receptor antagonist with a pharmacologic profile that differs from those of other drugs in its class. In addition to cardioselectivity mediated via β1 receptor blockade, nebivolol induces nitric oxide-mediated vasodilation by stimulating endothelial nitric oxide synthase via β3 agonism. This vasodilatory mechanism is distinct from those of other vasodilatory β-blockers (carvedilol, labetalol), which are mediated via α-adrenergic receptor blockade. Nebivolol is approved for the treatment of hypertension in the US, and for hypertension and heart failure in Europe. While β-blockers are not recommended within the current US guidelines as first-line therapy for treatment of essential hypertension, nebivolol has shown comparable efficacy to currently recommended therapies in lowering peripheral blood pressure in adults with hypertension with a very low rate of side effects. Nebivolol also has beneficial effects on central blood pressure compared with other β-blockers. Clinical data also suggest that nebivolol may be useful in patients who have experienced erectile dysfunction while on other β-blockers. Here we review the pharmacological profile of nebivolol, the clinical evidence supporting its use in hypertension as monotherapy, add-on, and combination therapy, and the data demonstrating its positive effects on heart failure and endothelial dysfunction.

Similar articles

See all similar articles

Cited by 10 articles

See all "Cited by" articles

References

    1. Munzel T, Gori T. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol. 2009;54:1491–1499. doi: 10.1016/j.jacc.2009.05.066. - DOI - PubMed
    1. Pedersen ME, Cockcroft J. The vasodilatory beta-blockers. Curr Hypertens Rep. 2007;9:269–277. doi: 10.1007/s11906-007-0050-2. - DOI - PubMed
    1. Bristow M, Nelson P, Minobe W, Johnson C. Characterization of β1-adrenergic receptor selectivity of nebivolol and various other beta-blockers in human myocardium. Am J Hypertens. 2005;18:A51–A52. doi: 10.1016/j.amjhyper.2005.03.139. - DOI
    1. Rosendorf C. Beta-blocking agents with vasodilator activity. J Hypertens. 1993;11:537. doi: 10.1097/00004872-199306003-00009. - DOI
    1. Bowman A, Chen C, Ford G. Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol. 1994;38:199–204. doi: 10.1111/j.1365-2125.1994.tb04342.x. - DOI - PMC - PubMed

Publication types

MeSH terms

Feedback